Want to see INBS full AI Analyst Report?
INBS Stock Chart & Stats
$1.03
-$0.03(-2.02%)
At close: 4:00 PM EST
$1.03
-$0.03(-2.02%)
Day’s Range― - ―
52-Week Range$2.08 - $24.90
Previous CloseN/A
Volume32.28K
Average Volume (3M)49.36K
Market Cap
$5.29M
Enterprise Value-$3.56M
Total Cash (Recent Filing)$6.86M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.52
Shares Outstanding2,391,846
10 Day Avg. Volume19,667
30 Day Avg. Volume49,360
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap-0.67
Enterprise Value/Revenue-0.91
Enterprise Value/Gross Profit-2.84
Enterprise Value/Ebitda0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-93.6
Revenue Forecast (FY)$14.65M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueA business model deriving recurring revenue from single-use cartridges creates predictable, high-frequency demand tied to testing volume. Durable consumable sales can stabilize revenue streams, improve lifetime customer value and support gross-margin leverage as device penetration expands across workplaces and corrections.
Modest Financial LeverageLow reported leverage provides financial flexibility versus highly indebted peers, limiting near-term interest burden and bankruptcy risk. That balance-sheet buffer helps the company sustain multi-quarter development and commercialization investments while it works to convert clinical progress into revenue growth.
Progress On FDA 510(k) Clinical PackageAdvancing structured clinical studies for FDA 510(k) clearance represents a durable strategic milestone: regulatory clearance would materially expand U.S. addressable market access, bolster trust with institutional buyers, and enable commercialization at scale, converting R&D spend into long-term revenue opportunities.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow at a multi-million dollar annualized pace creates ongoing financing needs. Over several quarters this erodes liquidity, constrains ability to invest in sales and manufacturing scale, and increases reliance on external capital, raising long-term sustainability risk.
Deep Operating Losses And Weak MarginsExtremely negative net margins and a declining gross margin indicate the current cost structure and product mix are not yet scalable. Until gross and operating margins improve through pricing, mix shift, or scale, profitability remains distant, limiting internal cash generation and compounding funding needs.
Equity Dilution RiskRepeated use of ATM offerings and sizable equity awards signals ongoing reliance on equity financing to fund operations. That increases dilution risk for shareholders and can depress per-share economics over time, reducing incentives for long-term investors unless operational cash generation improves.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions Inc.’s price range in the past 12 months?
Intelligent Bio Solutions Inc. lowest stock price was $2.08 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions Inc.’s market cap?
Intelligent Bio Solutions Inc.’s market cap is $5.29M.
When is Intelligent Bio Solutions Inc.’s upcoming earnings report date?
Intelligent Bio Solutions Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 117 days.
How were Intelligent Bio Solutions Inc.’s earnings last quarter?
Intelligent Bio Solutions Inc. released its earnings results on May 13, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.8.
Is Intelligent Bio Solutions Inc. overvalued?
According to Wall Street analysts Intelligent Bio Solutions Inc.’s price is currently Overvalued.
Does Intelligent Bio Solutions Inc. pay dividends?
Intelligent Bio Solutions Inc. does not currently pay dividends.
What is Intelligent Bio Solutions Inc.’s EPS estimate?
Intelligent Bio Solutions Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions Inc. have?
Intelligent Bio Solutions Inc. has 2,391,846 shares outstanding.
What happened to Intelligent Bio Solutions Inc.’s price movement after its last earnings report?
Intelligent Bio Solutions Inc. reported an EPS of -$1.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.472%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions Inc.?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
3.78% Insiders
0.63% Mutual Funds
7.03% Other Institutional Investors
88.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---